Abstract This study examined the cardiovascular effects of GLP-1 (7-36) or (9-36) on myocardial oxygen consumption, function and systemic hemodynamics in vivo during normal perfusion and during acute, regional myocardial ischemia. Lean Ossabaw swine received systemic infusions of saline vehicle or GLP-1 (7-36 or 9-36) at 1.5, 3.0, and 10.0 pmol/kg/min in sequence for 30 min at each dose, followed by ligation of the left circumflex artery during continued infusion at 10.0 pmol/kg/min. Systemic GLP-1 (9-36) had no effect on coronary flow, blood pressure, heart rate or indices of cardiac function before or during regional myocardial ischemia. Systemic GLP-1 (7-36) exerted no cardiometabolic or hemodynamic effects prior to ischemia. During ischemia, GLP-1 (7-36) increased cardiac output by approximately 2 L/min relative to vehicle-controls (p = 0.003). This response was not diminished by treatment with the non-depolarizing ganglionic blocker hexamethonium. Left ventricular pressurevolume loops measured during steady-state conditions with graded occlusion of the inferior vena cava to assess loadindependent contractility revealed that GLP-1 (7-36) produced marked increases in end-diastolic volume (74 ± 1 to 92 ± 5 ml; p = 0.03) and volume axis intercept (8 ± 2 to 26 ± 8; p = 0.05), without any change in the slope of the end-systolic pressure-volume relationship vs. vehicle during regional ischemia. GLP-1 (9-36) produced no changes in any of these parameters compared to vehicle. These findings indicate that short-term systemic treatment with GLP-1 (7-36) but not GLP-1 (9-36) significantly augments cardiac output during regional myocardial ischemia, via increases in ventricular preload without changes in cardiac inotropy.
Introduction
Full-length GLP-1 , endogenously produced by intestinal L-cells, is generally considered to be the physiologically active form of GLP-1 [11] . Administration of GLP-1 results in proportional increases in circulating GLP-1 (9-36) levels [21, 40] . Data on cardiovascular effects of these peptides are mixed: infusion of the or peptide has produced increased [3, 31] , decreased [24, 26, 36, 41] , or no change [19, 28, 35] in cardiac contractile function in normal hearts in rats, dogs and pigs. Effects of GLP-1 or to augment preloaddependent indices of cardiac function in ischemic and failing hearts [2, [27] [28] [29] 41] have been more clearly demonstrated, although again this effect is not consistently observed [30, 38] . Importantly, no study to date has directly assessed preload-independent measures of cardiac contractility in either normal or ischemic hearts. Therefore, whether improvements in cardiac contractile function induced by GLP-1 are mediated by direct inotropic effects, increases in ventricular diastolic filling (i.e., Frank-Starling effects), and/or cardioprotective mitigation of ischemic injury has not been defined. This set of studies was designed to evaluate the dosedependent effects of GLP-1 or (9-36) (1.5-10.0 pmol/kg/min, iv) on systemic hemodynamics, coronary flow, cardiac metabolism and preload-dependent and -independent measures of cardiac function in normal vs. ischemic hearts. Left ventricular pressure-volume relations were assessed in lean Ossabaw swine with highresolution admittance catheters before and during acute ligation of the left circumflex coronary artery. Inotropic status was directly evaluated by measuring the slope of the end-systolic pressure-volume relationship, using brief balloon occlusion of the inferior vena cava to produce graded reductions of ventricular preload. Our findings provide novel insight into the differential cardiovascular actions of GLP-1 isoforms and have important implications for the use of incretin-based therapies in circumstances of impaired cardiac function or ischemia.
Methods
All protocols were approved by the Institutional Animal Care and Use Committee in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Pub. No. 85-23, Revised 1996) and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Ossabaw Swine (n = 23) weighing between 66 and 83 kg were initially sedated with Telazol (tiletamin-zolazepam, 5 mg/ kg sc), xylazine (2.2 mg/kg sc), and ketamine (3.0 mg/kg sc). Subsequent to endotracheal intubation and venous access, anesthesia was maintained with morphine (3.0 mg/ kg sc) and a-chloralose (100 mg/kg, i.v.). Animals were mechanically ventilated (Harvard respirator) with O 2 -supplemented room air. Following completion of experimental protocols, hearts were fibrillated and excised in accordance with recommendation of the American Veterinary Medical Association Guide on Euthanasia (June 2007).
Surgical preparation
Acute in vivo experiments were conducted in open chest, anesthetized pigs. Catheters were placed into the right femoral artery and vein for systemic hemodynamic measurements and administration of supplemental anesthesia, heparin and sodium bicarbonate, respectively. A Fogarty balloon catheter (Edwards Lifesciences) was introduced into the left femoral vein and advanced into the inferior vena cava to allow for experimental reduction of venous return to the heart. Blood gas parameters were maintained within normal limits through periodic arterial blood gas analyses and appropriate adjustments to breathing rate and bicarbonate supplementation as necessary (arterial PO 2 , 180 ± 63 mmHg; arterial PCO 2 , 42 ± 1; pH, 7.4 ± 0.01; hematocrit, 35 ± 4). A left lateral thoracotomy was performed, allowing for access to the heart. The left circumflex artery (LCX) was then isolated and a suture placed loosely around it. At appropriate points in the study, this suture was used to ligate the LCX, thereby inducing regional myocardial ischemia. Next, the left anterior descending artery (LAD) was isolated and a perivascular flow transducer (Transonic Systems Inc.) was placed around the vessel. Following flow probe placement, a catheter was introduced into the coronary interventricular vein for coronary venous blood sampling. A pericardial cradle was then made to allow for adequate access to the heart apex and a purse string suture was placed at the apex through which an 18-gauge needle was passed into the LV cavity to allow for introduction and securing of a pressurevolume admittance catheter (Transonic Systems). All data were collected using IOX acquisition software (EMKA Technologies, Falls Church, VA, USA). Prior to any measurements, heparin was administered (bolus; 500 U/kg, iv) to prevent formation of blood clots during the protocol.
Experimental protocol
Animals were randomly assigned to study infusions, with no differences in pre-treatment management, surgical preparation, or study procedures other than the study infusion. A total of n = 23 animals were studied. This study employed four groups: vehicle treated (n = 5), GLP-1 (7-36) treated (n = 9), GLP-1 (9-36) treated (n = 5), GLP-1 (7-36) treated with concurrent hexamethonium (5 mg/kg, iv) administration (n = 3), and a single animal who was treated with epinephrine (n = 1). Following a stabilization period of at least 20 min, animals received continuous intravenous infusions of vehicle (saline), or graded infusions of increasing concentrations of GLP-1 or GLP-1 (9-36) at 1.5, 3.0, and 10.0 pmol/kg/min in sequence for 30 min at each dose. Following these infusions, the 10 pmol/kg/min was continued and the left coronary artery (LCX) was ligated to induce regional ischemia for an additional 30 min. In swine this ligation affects *20 % of the left ventricle [12] . The same animals that received graded vehicle or GLP-1 dosing also received coronary occlusion. However, only n = 5 of the GLP-1 (7-36)-treated animals were subjected to coronary ligation [i.e., 5 of the 9 GLP-1 (7-36)-treated pigs received LCX occlusion].
Aortic pressure, left ventricular pressure, left ventricular volume, coronary blood flow (LAD) and ECG were measured throughout the entire protocol. The left ventricular end-systolic pressure-volume relationship was assessed at each of the 30 min time points by a brief inflation (\5 s) of the Fogarty balloon catheter to reduce venous return.
Similar pressure-volume measurements were performed in the animal treated with epinephrine (10 lg/min) to demonstrate as a positive control the effects of a known inotrope on left ventricular pressure-volume relationships measured using this methodology.
Metabolic analysis
Arterial and coronary venous blood were collected simultaneously into untreated syringes, immediately sealed, and placed on ice. These samples were analyzed for pH, PCO 2 , PO 2 , O 2 content, and hematocrit with an Instrumentation Laboratories automatic blood gas analyzer (GEM Premier 3000) and CO-oximeter (682) system. Myocardial oxygen consumption (ll O 2 /min/g) was calculated using the Fick principle as [coronary blood flow 9 (arterial O 2 content -coronary venous O 2 content)]. For these calculations, LAD perfusion territory was estimated to be 30 % of total heart weight, as previously described by Feigl et al. [12] . Cardiac efficiency was calculated as the product of cardiac output (L/min) and mean arterial pressure (mmHg) divided by myocardial oxygen consumption (ll O 2 /min/g).
Statistical analyses
Data are presented as mean ± SE. Statistical comparisons were made with two-way (ANOVA) testing for differences between treatments in the dose response, and with one-way ANOVA comparing treatment groups under ischemia or comparing values within a treatment group before and after ischemia. For all comparisons, p B 0.05 was considered statistically significant. When significance was found with ANOVA, a Student-Newman-Keuls multiple comparison test was performed to identify differences between treatment levels and/or GLP-1 (7-36) or (9-36) vs. salineinfused time-controls.
Results

Hemodynamic and metabolic effects of acute GLP-1 administration
Effects of GLP-1 (7-36), GLP-1 (9-36) and time-control saline infusions on systemic hemodynamic variables are listed in Table 1 . Despite randomization to treatment conditions, modest (non-significant) differences in baseline blood pressure and heart rate were present between the treatment groups prior to GLP-1 administration. To avoid any bias resulting from this, we present results as absolute changes in these variables (Fig. 1 ). We observed a timedependent fall in blood pressure over the course of the experimental protocol that did not differ between groups (Fig. 1 ). Acute coronary occlusion had little additional effect on mean blood pressure in control or GLP-1 (9-36)-treated swine (Fig. 1c) . However, acute coronary occlusion was associated with a significant further decrease in mean blood pressure in GLP-1 (7-36)-treated animals (p \ 0.001). This decrease in arterial pressure was associated with a *20 beat/min increase in heart rate in GLP-1 Values are mean ± SE for time-control (n = 5), GLP-1 (7-36) (n = 9; n = 5 for LCX occlusion) and GLP-1 (9-36) (n = 5) (7-36)-treated swine relative to identically handled salineinfused time-control animals ( Fig. 1d ; p = 0.001). Consistent with the changes in blood pressure, coronary flow and myocardial oxygen consumption in the nonischemic LAD region tended to decrease in all treatment groups (Table 1) . Reductions in coronary flow were statistically greater relative to within group baseline in GLP-1 (7-36)-treated swine at the 3.0 (p = 0.006) and 10.0 pmol/ kg/min (p = 0.019) exposure as well as during regional myocardial ischemia (p = 0.013). However, absolute coronary blood flows were not different between time-control and GLP-1-treated swine at any time point before or during ischemia (Table 1 ). No differences in myocardial oxygen consumption were detected between groups at any treatment condition (Table 1) .
Cardiac effects of acute GLP-1 administration
Administration of GLP-1 (7-36) or (9-36) had no effect on left ventricular diastolic filling, stroke volume, cardiac output or ejection fraction over the 1.0-10.0 pmol/kg/min dose range prior to the induction of myocardial ischemia (Table 2) . However, during regional ischemia GLP-1 (7-36) treatment was significantly associated with increased left ventricular end-diastolic volume (75 ± 1 vs. 92 ± 5 ml; p = 0.016), and stroke volume (32 ± 6 vs. 48 ± 6 ml; p = 0.040), without differences in end-systolic volume or ejection fraction relative to time-control animals ( Table 2 ). These alterations in cardiac function were also evident when analyzed as absolute changes relative to their respective baseline values (Fig. 2) . One of the most striking findings of this study is the approximate 2 L/min increase in cardiac output (p = 0.015 within group; p \ 0.001 relative to time-control) observed in GLP-1 (7-36)-treated swine during regional ischemia (Fig. 2d) . This effect was specific to the (7-36) peptide, as these variables were unaffected by the onset of myocardial ischemia in time-control or (9-36)-treated swine.
Steady-state pressure-volume loops demonstrating the effect of GLP-1 administration at the 10 pmol/kg/min dose before and during regional ischemia are presented in Fig. 3 . These loops, presenting averaged pressure-volume data from representative animals, demonstrate the lack of an effect of regional ischemia on the left ventricular pressure-volume relationship under control conditions (Fig. 3a) . To demonstrate the effects of a classic positive inotropic (contractility) and chronotropic (heart rate) response in our preparation, left ventricular pressure- volume loops were determined during the administration of intravenous epinephrine (10 lg/min) in one animal under normal perfusion conditions (Fig. 3b) . Epinephrine produced a marked upward-leftward shift in the pressurevolume loop as a result of substantial increases in ventricular systolic pressure (*200 mmHg) and decreases in end-systolic and end-diastolic volumes (consequence of heart rates [200 beats/min). Note the change in scale of Fig. 3b ; the dashed line represents the maximal Y scale value of other panels. Consistent with previous data [28] , GLP-1 (9-36) had no effect on pressure-volume parameters in normal or ischemic hearts (Fig. 3d) . In contrast, infusion of GLP-1 (7-36) (10 pmol/kg/min) during regional myocardial ischemia resulted in diminished left ventricular pressure generation and a notable right shift of the pressure-volume relationship; i.e., increased left ventricular end-diastolic volume (preload) (Fig. 3c) . Effects of GLP-1 peptides on Ees and V 0 are found in Table 2 . Neither GLP-1 (7-36) nor (9-36) influenced Ees at any dose, regardless of experimental condition. Despite the lack of change in slope of ESPVR, GLP-1 (7-36) significantly increased V 0 at the 10.0 pmol/kg/min dose, both before and during regional myocardial ischemia (Table 2) . V 0 was unchanged in time-control and GLP-1 (9-36)-treated swine. Plotting the relationship between cardiac output and end-diastolic volume (FrankStarling relationship) during regional ischemia demonstrates that the increase in cardiac output in GLP-1 (7-36)-treated swine is directly related to increases in end-diastolic volume (preload) (Fig. 4) , without any apparent contribution from direct effects on contractility. Examination of the time constant of ventricular relaxation (Tau ) suggests that administration of GLP-1 (7-36) improved diastolic function during LCX occlusion (Table 2 ). In contrast, Tau tended to worsen with LCX occlusion in time-control and GLP-1 (9-36)-treated animals.
To assess whether the effects of GLP-1 (7-36) are mediated centrally, additional studies were performed in the presence of the non-depolarizing ganglionic blocker hexamethonium (n = 3). Results of these studies are included in Fig. 4 and demonstrate that both cardiac output and end-diastolic volume are elevated in the ischemic heart Values are mean ± SE for time-control (n = 5), GLP-1 (7-36) (n = 5) and GLP-1 (9-36) (n = 5) with GLP-1 (7-36) treatment regardless of hexamethonium administration. Additional examination of the effects of GLP-1 on cardiac efficiency [cardiac output (L/min) 9 mean arterial pressure (mmHg)]/myocardial oxygen consumption (ll O 2 min/g) demonstrated no effect of vehicle, GLP-1 or (9-36) administration under baseline-control conditions (Fig. 5) . However, cardiac efficiency was significantly augmented by GLP-1 (7-36) administration during regional myocardial ischemia (Fig. 5) . GLP-1 (9-36) had no effect on cardiac efficiency during ischemia.
Discussion
This investigation examined the effects of systemically infused GLP-1 (7-36) and (9-36) on systemic hemodynamics, coronary flow and preload-dependent and -independent measures of cardiac function in normal and ischemic hearts. Neither GLP-1 isoform had any effect on systemic pressure, coronary blood flow or cardiac function in normally perfused hearts relative to saline-infused timecontrols. Moreover, GLP-1 (9-36) had no effect on any measured cardiovascular parameter in normal or ischemic hearts. In contrast, the induction of regional ischemia during GLP-1 (7-36) administration produced significant reductions in systemic blood pressure *20 mmHg and increased cardiac output and efficiency. Pressure-volume analyses revealed that this (7-36)-mediated increase in cardiac performance was not associated with any change in myocardial contractility (as assessed by ESPVR), but was accompanied by a significant increase in left ventricular end-diastolic volume and an increase in volume axis intercept (V 0 ). Together these observations demonstrate that acute administration of GLP-1 (7-36) significantly augments cardiac output during regional myocardial ischemia via increases in ventricular preload, independent of changes in cardiac inotropy (i.e., Frank-Starling mechanism). The findings further indicate that GLP-1 (9-36) is unlikely to significantly contribute to improvements in cardiovascular function produced by GLP-1 (7-36) in ischemic hearts.
Hemodynamic effects of GLP-1 Consistent with previous studies from our laboratory and others [23, 24, 28] , we found that short-term treatment with GLP-1 (7-36) had no effect on coronary flow or myocardial oxygen consumption under any experimental condition (Table 1) . Therefore, improvements in cardiac function observed in response to GLP-1 (7-36) cannot be the result of differences in myocardial perfusion. GLP-1 (7-36) also had no effect on systolic, diastolic or mean blood pressure relative to identically handled time-control animals in nonischemic hearts. This lack of a pressor effect in otherwise healthy hearts is consistent with previous investigations in saline and vs GLP-1 human subjects [7, 24, 32, 33, 35] , but contrasts with the findings in rodent models which largely report hypertensive effects of GLP-1 [4-6, 8, 15, 19, 39] . However, we did observe significant reductions in blood pressure in GLP-1 (7-36)-treated swine during regional myocardial ischemia (Fig. 1) . This hypotensive effect has also been reported by other labs in the setting of various pathologic conditions such as ischemia-reperfusion injury, myocardial infarction and heart failure [27, 28, 35] .
Inotropic effects of GLP-1 Prior evidence supports the ability of GLP-1-based therapies to augment preload-dependent indices of cardiac function (e.g., dP/dt, developed pressure, cardiac output) in ischemic and failing hearts [3, 27, 28, 32, 41] . This effect is also evident in the current studies by the marked increase in cardiac output in GLP-1 (7-36)-treated swine following the induction of regional myocardial ischemia (Fig. 2d) . However, no prior study has directly assessed preloadindependent measures of cardiac contractility in response to GLP-1 to distinguish true inotropic effects from FrankStarling effects. This distinction has important implications for the clinical circumstances where these effects can be used to advantage, or importantly where the true nature of the effects might imply adverse outcomes. In order to examine this key issue, we employed high-sensitivity pressure-volume catheters to obtain end-systolic pressurevolume relationships (ESPVR), the ''gold-standard'' measure of cardiac inotropy [9, 34] . ESPVR is experimentally measured by progressive reductions in ventricular preload via transient balloon occlusion of the inferior vena cava, such that increases in contractility (inotropy) augment pressure at a given ventricular volume resulting in an elevation in the slope of ESPVR (see effect of 10 lg/min epinephrine in Fig. 3b ). In the current study, GLP-1 (7-36) did not affect the slope of ESPVR at any dose in normal hearts, or following acute ligation of the left circumflex coronary artery. These findings indicate that GLP-1-mediated increases in cardiac output observed following the onset of acute, regional ischemia are independent of changes in myocardial contractility. However, our data do not address the potential inotropic effects of longer term GLP-1 administration, an avenue meriting future studies.
Starling effects of GLP-1 Preload-independent assessments of cardiac contractility include two key measurements: slope of ESPVR and the volume axis intercept (V 0 , ventricular volume at zero pressure). Under controlled conditions, a shift in V 0 indicates a volume-dependent action on contractile force making V 0 a suitable index of the Frank-Starling mechanism. We found that 10.0 pmol/kg/min GLP-1 (7-36) administration significantly increased V 0 in both normal and ischemic hearts (Table 2) . Additionally, GLP-1 (7-36) treatment significantly increased left ventricular end-diastolic volume ( Fig. 2a) with no significant change in end-systolic volume (Fig. 2b) during regional ischemia. This phenomenon is readily apparent by examination of averaged left ventricular pressure-volume relationships at the 10.0 pmol/kg/min dose (vehicle or GLP-1 analogues) during normal perfusion and ischemia (Fig. 3) and by examination of the relationship between end-diastolic volume and cardiac output in Fig. 4 . This effect was maintained in the presence of the non-depolarizing ganglionic blocker hexamethonium (Fig. 4) . Taken together, these findings indicate that acute administration of GLP-1 (7-36) significantly increases in cardiac output mediated through a preload-dependent, Frank-Starling effect via effects on the heart itself as opposed to via centrally mediated processes.
Since the initial description of load-dependent changes in cardiac contractile force [20] , numerous molecular phenomena have been implicated as the mechanism of cardiac heteromeric autoregulation (i.e., Frank-Starling responses) [1, 9, 10, 12-14, 16, 17, 32] . While the precise mechanisms responsible for this effect of GLP-1 (7-36) remain unclear, it is important to point out that the increases in cardiac output occurred without concomitant increase in myocardial oxygen consumption; i.e., GLP-1 (7-36) augmented cardiac efficiency during ischemia (Fig. 5) . We postulate this effect is related at least in part to optimization of the myocellular contractile apparatus (i.e., Starling effect) and/or energetically favorable alterations in myocardial substrate metabolism (i.e., augmented glucose uptake) [18, 22, 23, 25, 37] . Understanding of these mechanisms could have significant therapeutic relevance for development of energetically favorable therapies for heart failure.
Conclusion
Short-term systemic exposure to GLP-1 (7-36) augments cardiac output under conditions of ischemia through increases in preload (Frank-Starling mechanism) without direct effects on contractility or other centrally mediated phenomena. This ''Starling'' response was facilitated by enhanced cardiac relaxation as indicated by elevations in V 0 . Neither GLP-1 (7-36) nor (9-36) affected coronary flow or systemic pressure regulation, and in contrast to intact GLP-1 , the GLP-1 (9-36) fragment did not exert any effects on cardiac output during ischemia. Taken together, these results support a role for GLP-1 in enhancing cardiac output under conditions of regional myocardial ischemia. This enhancement is energetically favorable as the process is a passive response resulting from facilitation of diastolic filling as opposed to an active inotropic mechanism.
